伦瓦提尼布剂量升级策略对差异化甲状腺癌的临床影响
Ryutaro Onaga1,2, Tomohiro Enokida1, Susumu Okano1
1Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa-shi, Chiba, 277-8577, Japan.
International journal of clinical oncology
|July 23, 2024
概括
在治疗进展的分化甲状腺癌 (DTC) 患者中,增加伦瓦提尼布的剂量提供了一个安全有效的选择. 这一策略显著改善了整体存活率,与治疗结束相比.
科学领域:
- 在瘤学瘤学.
- 甲状腺癌研究研究
- 药理学研究 药理学研究
背景情况:
- 差异化甲状腺癌 (DTC) 患者在患病进展后经常面临有限的治疗选择.
- 氨酸激酶抑制剂 (TKIs) 的剂量升级在各种癌症中得到了探索,但其在DTC中的临床意义仍未得到研究.
研究的目的:
- 评估伦瓦提尼布剂量升级在经历疾病进展的DTC患者的安全性和有效性.
- 为了比较接受剂量升级伦瓦提尼布的患者和终止治疗的患者之间的结果.
主要方法:
- 对从2011年9月至2022年6月接受伦瓦提尼布治疗的DTC患者的回顾性评估.
- 对那些接受了剂量升级的伦瓦提尼布患者与在疾病进展时终止治疗的患者进行比较.
- 剂量升级的决定是基于以前有效和耐受剂量.
主要成果:
- 15名患者接受了剂量升级,18名患者终止治疗;进展时的伦瓦提尼布中位数剂量为10毫克/天.
- 剂量升级组的客观反应率为13.3%,临床益处率为73.3%.
- 在剂量升级组中,从初始进展开始的平均整体存活时间显著更长 (20.4个月与3.9个月相比; p=0.0004).
结论:
- 伦瓦提尼布剂量升级是DTC患者在疾病进展后的安全有效策略.
- 这种方法提供了可行的治疗选择,改善了生存结果.
- 没有报告5级不良事件;一名患者因3级肺而停止治疗.
更多相关视频
03:55Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer
Published on: June 9, 2023
514
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
8.8K
相关概念视频
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
01:11Renal Failure: Dose Adjustments
78
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
78